常山藥業(300255.SZ)：擬變更相關募集資金用途
格隆匯12月13日丨常山藥業(300255.SZ)公佈，公司於2021年12月13日召開第四屆董事會第十七次會議及第四屆監事會第十二次會議，審議通過了《關於變更募集資金用途的議案》。公司結合實際經營和業務發展需要，為提高募集資金使用效率，擬變更2016年度非公開發行募集資金投資項目“多糖及蛋白質多肽系列產品產業化項目”(“原募投項目”)。
公司的多糖及蛋白質多肽系列產品產業化項目擬建設小容量注射劑製劑車間預充式生產線，原計劃建設4條帶開放式隔離器製劑生產線，達產後年產8000萬支低分子肝素製劑。募集資金到位後，公司立即開展募投項目的各項建設籌備工作。
在籌備過程中，一方面外部市場環境發生變化，公司低分子肝素製劑產品的實際市場需求與預期有所差異，2016年至2020年公司肝素製劑銷量平均增速為12.38%，低於募投項目立項時預計的未來增速；另一方面，由於工藝技術的進步，經過公司驗證，通過建設封閉式隔離器製劑生產線能大幅降低投資成本並提高產能。因此公司根據業務發展情況對項目進行重新諮詢、論證和設計，將建設4條帶開放式隔離器製劑生產線改為建設1條帶封閉式隔離器預充生產線。
調整後的小容量注射劑製劑車間擴產項目產能仍為年產8000萬支小容量注射劑，調整後的項目投資總額為19109.82萬元，已投入募集資金18037.82萬元，後續項目建設預計需要1072萬元資金，由於調整後的項目總建設週期較長，為提高募集資金使用效率，公司擬使用自有資金根據公司製劑銷售需要繼續建設該項目，以滿足公司未來肝素製劑銷售需求。
公司現有普通肝素原料藥產能為50,000億單位、依諾肝素鈉原料藥產能為2500公斤，在行業中規模較小。新建“年產35噸肝素系列原料藥產品項目”可以與公司現有產業鏈協同補齊公司肝素原料藥產能短板，使用募集資金建設該項目，可以提高募集資金使用效率，且具有良好的經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
